V8 Peptides — Engineered Performance
Research Library
Tesamorelin: The Hexenoyl Modification Explained
TesamorelinChemistry

Tesamorelin: The Hexenoyl Modification Explained

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What makes tesamorelin different from native GHRH? Tesamorelin is a synthetic analog of growth-hormone-releasing hormone with a trans-3-hexenoyl group attached to the N-terminal tyrosine. Native GHRH is cleaved within minutes by dipeptidyl peptidase IV (DPP-IV) after its second residue, and the N-terminal cap is designed to block that first cut while leaving the GHRH receptor-binding portion intact. The V8 product page lists a 10 mg lyophilized vial at ≥98% HPLC purity with molecular formula C221H366N72O67S, described as a stabilized GHRH (1-44) analog. This article focuses on that one modification: why it was made, what chemistry it does and does not change, and what it means for assay design and handling. For laboratory research use only.

Tesamorelin is often discussed alongside other growth hormone axis peptides, but its defining feature is a chemical one. A single acyl group, added to one amino acid, changes how the peptide survives in plasma and in assay media. This guide takes the molecule apart from that angle, to complement the broader tesamorelin research overview. The discussion concerns in vitro and preclinical laboratory work; the compound is for laboratory research use only and is not for human consumption.

Native GHRH and its weak point

Growth-hormone-releasing hormone was first characterized in the early 1980s, when Rivier and colleagues isolated and sequenced a releasing factor from a human pancreatic islet tumour. The hypothalamic hormone exists as a 44-residue amidated peptide, and the first 29 residues are sufficient for full receptor activity in standard assays. That shorter 1–29 fragment is the core of several analogs, including the CJC-1295 (No DAC) material, which is based on a modified GRF 1–29 sequence.

The weakness of the native sequence is its N-terminus. Frohman and colleagues (1989) showed that human GHRH incubated in plasma is degraded by dipeptidylpeptidase IV, which removes the Tyr-Ala dipeptide, and by trypsin-like enzymes at basic residues. The N-terminally truncated product is much less active. In vitro, that means a short and variable half-life in any medium containing serum or plasma enzymes. A second route, described for GRF analogs in neutral aqueous solution by Friedman and colleagues (1991), is chemical: deamidation of asparagine residues over time.

The structural modification

The product page gives the N-terminal region of tesamorelin as trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg, followed by the remainder of the 44-residue chain. Compared with native human GHRH, the one deliberate change is the six-carbon unsaturated acyl group on the amine of tyrosine-1. In the preclinical literature this molecule was developed under the code TH9507, and Ferdinandi and colleagues (2007) describe its non-clinical pharmacology.

PropertyNative GHRH (1-44)Tesamorelin
N-terminusFree amine on Tyr-1Amine acylated with trans-3-hexenoyl
DPP-IV susceptibilityCleaved between Ala-2 and Asp-3Cleavage reduced by the cap, as reported in the non-clinical literature
Receptor-binding regionN-terminal 1–29Same sequence, same region
Length44 residues, amidated C-terminus44 residues
IsomerNot applicableTrans double bond between carbons 3 and 4 of the acyl chain
HydrophobicityModerateSlightly raised by the acyl group

Two points deserve emphasis. First, the cap protects only against enzymes that need a free N-terminal amine. Trypsin-like cleavage at lysine and arginine, deamidation and methionine oxidation are not affected by it. Second, the double bond in the acyl chain is a potential site of oxidation, so protection from light and air is a more relevant precaution than it would be for a saturated acyl group.

Where it acts in an assay

Tesamorelin binds the GHRH receptor, a class B G-protein-coupled receptor on pituitary somatotrophs that signals through Gαs and cAMP. Cunha and Mayo (2002) used cells expressing transfected GHRH and secretagogue receptors to show that cAMP production is a measurable readout and that agonists of the second receptor can potentiate it, a design useful for anyone comparing GHRH analogs with ghrelin-receptor agonists. Typical readouts for a GHRH analog include:

  • cAMP accumulation in a cell line expressing the GHRH receptor, with native GHRH as the reference agonist.
  • Growth hormone release from primary rat pituitary cells.
  • CREB phosphorylation as a downstream marker.
  • Receptor desensitization or internalization after sustained exposure.

The structural point matters in two ways. In serum-containing medium, a stabilized analog stays at its nominal concentration longer than native GHRH, so the comparison depends on the medium. In serum-free buffer the difference shrinks, which can be used as an internal control: if a gap in activity vanishes without serum, it was a stability gap, not an affinity gap.

Design questionSuggested approachWhat it separates
Stability or affinity?Run in serum-free buffer and in serum-containing mediumEnzymatic breakdown from receptor-level potency
Is the signal receptor-mediated?Add a GHRH receptor antagonist, or use receptor-null cellsSpecific from non-specific cAMP
Is the cap necessary?Compare with the uncapped 1–29 sequence from the same sourceContribution of the hexenoyl group
Combination effectsPair with a ghrelin-receptor agonist and measure cAMP and GH releaseAdditive from potentiating behavior
Compound integrityRe-check by HPLC after incubationReal loss from apparent loss

Comparing tesamorelin with related GHRH analogs

Several GHRH-based peptides are used as reference ligands, and they differ in the strategy used to resist breakdown. Tesamorelin vs sermorelin contrasts the capped 44-residue molecule with the unmodified 1–29 fragment. Tesamorelin vs CJC-1295 sets it beside a 1–29 analog with amino acid substitutions that stabilize the sequence internally. CJC-1295 DAC vs No DAC adds a third strategy, binding to serum albumin through a reactive linker. Each design solves the same problem differently, and each leaves different weak points for the bench scientist to manage.

Handling a stabilized but not indestructible peptide

The tesamorelin product page lists lyophilized powder in a sealed clear glass research vial and states storage at 2–8 °C, −20 °C for long-term, protected from heat, moisture and light. Chemical pathways in aqueous peptide and protein solutions are reviewed by Manning and colleagues (2010), and the stresses that reveal them in forced-degradation studies by Hawe and colleagues (2012). For this sequence the points that stand out are:

  • Deamidation. The sequence contains Asn-8 and Gln residues. Friedman and colleagues linked the aqueous instability of GRF analogs to asparagine deamidation, which is promoted by neutral to alkaline pH and warmth. Keep solutions cold and avoid alkaline buffers.
  • Methionine oxidation. A single methionine sits near the C-terminal end of the 1–29 portion. Oxygen exposure and trace metals can convert it to the sulfoxide, which shifts the HPLC retention time.
  • Surface loss. A 44-residue peptide with many basic residues adsorbs to glass and plastic; Goebel-Stengel and colleagues (2011) describe the effect and suggest low-binding labware.
  • Aggregation. Foaming and shaking encourage aggregation of a peptide of this size. Swirl gently.

Concentration is vial mass divided by diluent volume, and the reconstitution calculator carries out the arithmetic; the tesamorelin reconstitution and storage guide covers the procedure. The sealed vial's contents are documented on the batch certificate where one is published, found through the COA library; tesamorelin purity testing explains what to look for in the chromatogram, including closely eluting oxidized and deamidated species.

Verifying that the cap is still on

Because the hexenoyl group is the point of the molecule, it is reasonable to confirm that the material in a vial still carries it. In reverse-phase HPLC the acylated peptide is retained a little longer than an uncapped relative, so a small early-eluting shoulder can indicate material that has lost or never received the group. Mass-based identity data, where a certificate reports them, show the expected shift from the added acyl group; the HPLC identity-testing comparison explains what each technique can establish. A change in the pattern after storage is informative: a growing peak slightly earlier than the main one often points to deamidation, while a later-eluting or split peak can reflect oxidation of the methionine or isomerization of the double bond. Keeping a retained chromatogram from the first preparation gives a baseline for those comparisons, and a re-run at the end of a long experiment shows whether the stock changed while the data were being collected. None of this requires special equipment beyond the HPLC method already used for the purity check.

Documentation checklist

  • Lot number and purity from the certificate, where published.
  • Diluent type and lot; preservative included in the vehicle control.
  • Vial mass, volume added, resulting stock concentration (formula: mass ÷ volume).
  • Appearance at preparation: clear and colorless; record any haze.
  • Number of freeze–thaw cycles for each aliquot; plan for one.
  • For serum-containing assays, the serum lot and the incubation time at 37 °C.

For context on the wider category, see what is tesamorelin, where to buy tesamorelin and the shop. The material is supplied for laboratory research use only; nothing here is a recommendation for use in people or animals.

Frequently asked questions

What is the key structural feature of tesamorelin?

A trans-3-hexenoyl group on the N-terminal tyrosine of a 44-residue GHRH-based sequence. It is designed to block cleavage by dipeptidyl peptidase IV.

Why does native GHRH break down so quickly in plasma?

DPP-IV removes the N-terminal Tyr-Ala dipeptide, and trypsin-like enzymes cut at basic residues, as described by Frohman and colleagues in 1989. The truncated product is far less active.

Does the hexenoyl cap protect against every kind of degradation?

No. It targets enzymes that need a free N-terminal amine. Deamidation, methionine oxidation, adsorption and aggregation are unaffected.

What formula and size does the product page list?

The page lists a 10 mg lyophilized vial at ≥98% HPLC purity with molecular formula C221H366N72O67S.

How can an experiment separate stability from potency?

Run the same assay in serum-free buffer and in serum-containing medium. If a difference between analogs disappears without serum, it was a stability difference.

Which receptor does it act on in assays?

The GHRH receptor, a class B G-protein-coupled receptor that signals mainly through cAMP in pituitary somatotroph models.

Is tesamorelin the same as sermorelin or CJC-1295?

No. All three are GHRH-based, but sermorelin is the unmodified 1–29 fragment, CJC-1295 is a substituted 1–29 analog, and tesamorelin is a capped 44-residue analog.

How should the sealed vial be stored?

The product page states 2–8 °C, with −20 °C for the long term, protected from heat, moisture and light.

What are the main chemical risks in solution?

Asparagine deamidation at neutral to alkaline pH, oxidation of methionine and the acyl double bond, surface adsorption and aggregation from agitation.

Is tesamorelin sold for use in people or animals?

No. It is supplied for laboratory research use only and is not for human or animal consumption.

Related reading: Tesamorelin Shelf Life and Long-Term Stability.

References

  1. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276-278. doi:10.1038/300276a0
  2. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. doi:10.1172/JCI114049
  3. Friedman AR, Ichhpurani AK, Brown DM, Hillman RM, Krabill LF, Martin RA, Zurcher-Neely HA, Guido DM. Degradation of growth hormone releasing factor analogs in neutral aqueous solution is related to deamidation of asparagine residues. Int J Pept Protein Res. 1991;37(1):14-20. doi:10.1111/j.1399-3011.1991.tb00727.x
  4. Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. doi:10.1111/j.1742-7843.2007.00008.x
  5. Cunha SR, Mayo KE. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-4582. doi:10.1210/en.2002-220670
  6. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
  7. Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
  8. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.